Compare Stocks: CLDX, PCVX, KRYS, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$28.97 -1.4%	$35.42	$22.10 ▼ $45.14	$2.31B	0.9	1.69 million shs	877,931 shs
KRYS Krystal Biotech	$320.13 -0.6%	$339.77	$183.03 ▼ $382.54	$9.54B	0.5	274,591 shs	245,203 shs
PCVX Vaxcyte	$62.85 -0.6%	$61.54	$39.87 ▼ $90.75	$9.41B	1.23	3.81 million shs	2.77 million shs
PTGX Protagonist Therapeutics	$139.40 +1.0%	$144.35	$73.08 ▼ $160.81	$8.93B	1.53	844,449 shs	404,382 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-3.04%	+5.53%	-22.49%	-17.08%	+5.23%
KRYS Krystal Biotech	-1.00%	-2.58%	-3.50%	-1.63%	+68.87%
PCVX Vaxcyte	-4.53%	-6.40%	+7.32%	+13.64%	+49.30%
PTGX Protagonist Therapeutics	+0.07%	+1.32%	-4.76%	+1.96%	+84.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$28.97 -1.4%	$35.42	$22.10 ▼ $45.14	$2.31B	0.9	1.69 million shs	877,931 shs
KRYS Krystal Biotech	$320.13 -0.6%	$339.77	$183.03 ▼ $382.54	$9.54B	0.5	274,591 shs	245,203 shs
PCVX Vaxcyte	$62.85 -0.6%	$61.54	$39.87 ▼ $90.75	$9.41B	1.23	3.81 million shs	2.77 million shs
PTGX Protagonist Therapeutics	$139.40 +1.0%	$144.35	$73.08 ▼ $160.81	$8.93B	1.53	844,449 shs	404,382 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-3.04%	+5.53%	-22.49%	-17.08%	+5.23%
KRYS Krystal Biotech	-1.00%	-2.58%	-3.50%	-1.63%	+68.87%
PCVX Vaxcyte	-4.53%	-6.40%	+7.32%	+13.64%	+49.30%
PTGX Protagonist Therapeutics	+0.07%	+1.32%	-4.76%	+1.96%	+84.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.77	Moderate Buy	$63.08	117.75% Upside
KRYS Krystal Biotech	3.00	Buy	$377.20	17.83% Upside
PCVX Vaxcyte	2.67	Moderate Buy	$110.50	75.82% Upside
PTGX Protagonist Therapeutics	3.11	Buy	$158.19	13.48% Upside

Current Analyst Ratings Breakdown

Latest CLDX, PCVX, KRYS, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	PTGX Protagonist Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$155.00 ➝ $160.00
10/15/2026	CLDX Celldex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$361.00
10/14/2026	PTGX Protagonist Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/12/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$184.00
10/12/2026	PCVX Vaxcyte	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$120.00
10/12/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/12/2026	PTGX Protagonist Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$150.00 ➝ $190.00
10/9/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B) ➝ Buy (B-)
10/8/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$1.54M	1,477.28	N/A	N/A	$7.93 per share	3.65
KRYS Krystal Biotech	$389.13M	24.35	$7.24 per share	44.19	$42.06 per share	7.61
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
PTGX Protagonist Therapeutics	$46.02M	196.01	N/A	N/A	$9.83 per share	14.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	40.37	35.57	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	134.06	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest CLDX, PCVX, KRYS, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CLDX Celldex Therapeutics	-$1.02	N/A	N/A	N/A	$0.72 million	N/A
11/5/2026	Q3 2026	PTGX Protagonist Therapeutics	$2.50	N/A	N/A	N/A	$238.49 million	N/A
11/3/2026	Q3 2026	PCVX Vaxcyte	-$2.11	N/A	N/A	N/A	$12.50 million	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.82	N/A	N/A	N/A	$126.22 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	11.82	11.82
KRYS Krystal Biotech	N/A	8.32	7.96
PCVX Vaxcyte	N/A	5.72	5.72
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
KRYS Krystal Biotech	86.29%
PCVX Vaxcyte	96.78%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	5.20%
KRYS Krystal Biotech	13.10%
PCVX Vaxcyte	3.30%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
PCVX Vaxcyte	507	148.80 million	143.89 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable

CLDX, PCVX, KRYS, and PTGX Headlines

Recent News About These Companies

Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)

October 19 at 8:14 AM | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research

October 16, 2026 | marketbeat.com

Citi keeps Buy rating for Protagonist Therapeutics stock

October 15, 2026 | ad-hoc-news.deA

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know

October 15, 2026 | zacks.com

Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group

October 14, 2026 | marketbeat.com

UBS sets USD 184.00 target for Protagonist Therapeutics stock

October 13, 2026 | ad-hoc-news.deA

Head to Head Contrast: Protagonist Therapeutics (NASDAQ:PTGX) & AbCellera Biologics (NASDAQ:ABCL)

October 13, 2026 | americanbankingnews.com

UBS initiates coverage of Protagonist Therapeutics with buy rating

October 12, 2026 | msn.com

Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology

October 12, 2026 | msn.com

UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target

October 12, 2026 | marketscreener.comM

Protagonist Therapeutics' (PTGX) Outperform Rating Reaffirmed at Leerink Partners

October 12, 2026 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners

October 12, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) & Halozyme Therapeutics (NASDAQ:HALO) Financial Survey

October 11, 2026 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen

October 10, 2026 | marketbeat.com

Protagonist Therapeutics stock fell 1.38 percent on October 6

October 6, 2026 | ad-hoc-news.deA

Protagonist Therapeutics (NASDAQ:PTGX) Stock: Insider Asif Ali Sells 58,629 Shares

October 3, 2026 | insidertrades.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock

October 2, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts

October 2, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?

September 25, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 Shares

September 11, 2026 | insidertrades.com

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, PCVX, KRYS, and PTGX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$28.97 -0.40 (-1.36%)

Closing price 04:00 PM Eastern

Extended Trading

$28.96 0.00 (-0.02%)

As of 07:30 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Krystal Biotech NASDAQ:KRYS

$320.13 -2.04 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$317.42 -2.71 (-0.85%)

As of 07:37 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Vaxcyte NASDAQ:PCVX

$62.85 -0.38 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$62.06 -0.79 (-1.25%)

As of 07:50 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Protagonist Therapeutics NASDAQ:PTGX

$139.40 +1.32 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$139.64 +0.24 (+0.17%)

As of 07:30 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDX, PCVX, KRYS, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDX, PCVX, KRYS, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDX, PCVX, KRYS, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, PCVX, KRYS, and PTGX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Krystal Biotech NASDAQ:KRYS

Vaxcyte NASDAQ:PCVX

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDX, PCVX, KRYS, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDX, PCVX, KRYS, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDX, PCVX, KRYS, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, PCVX, KRYS, and PTGX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Krystal Biotech NASDAQ:KRYS

Vaxcyte NASDAQ:PCVX

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools